CIRB Studies

Below is the current list of studies covered by the CIRB. Participants should refer to ClinicalTrials.gov for general information about clinical trials. Institutions should refer to the Clinical Trials Support Unit (CTSU) website  for enrollment requirements and accrual status information. 

Study documents approved after July 1, 2013 are available to participating institutions for covered studies on the CTSU website. To request documents approved before July 1, 2013, participating institutions can contact the CIRB Helpdesk.

Review CIRB
Study Number Network Study Title CIRB
AAML0531 COG A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined with Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children; Adolescents; and Young Adults Pediatric CIRB
AAML05P1 COG Killer Immunoglobulin-like Receptor (KIR) Incompatible Unrelated Donor Hematopoietic Stem Cell Transplantation (SCT) for AML with Monosomy 7; -5/5q-; High FLT3-ITD AR; or Refractory and Relapsed Acute Myelogenous Leukemia (AML) in Children: A Children's Oncology Group (COG) Study (A Groupwide Pilot Study) Pediatric CIRB
AAML0631 COG Risk Adapted Treatment of Newly Diagnosed Childhood Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide (Trisenox IND# 103, 331) during Consolidation: A Phase III Study Limited to COG institutions in the United States & Canada Pediatric CIRB
AAML06P1 COG A Pilot Study of Lestaurtinib (CEP-701) in Combination with Chemotherapy in Young Patients with Relapsed or Refractory FLT3-mutant Acute Myeloid Leukemia Pediatric CIRB
AAML07P1 COG A Phase II Pilot Study of Bortezomib (PS-341; Velcade; IND# 58;443) Combined with Reinduction Chemotherapy in Children and Young Adults with Recurrent; Refractory or Secondary Acute Myeloid Leukemia Pediatric CIRB
AAML08B1 COG Biology Study of Transient Myeloproliferative Disorder (TMD) in Children with Down Syndrome (DS) Pediatric CIRB
AAML1031 COG A Phase III Randomized Trial for Patients with de novo AML using Bortezomib and Sorafenib (IND#114480; NSC# 681239; NSC# 724772) for Patients with High Allelic Ratio FLT3/ITD Pediatric CIRB
AAML1331 COG A Phase III Study for Patients with Newly Diagnosed Acute Promyelocytic Leukemia (APL) using Arsenic Trioxide and All-Trans Retinoic Acid: A COG Groupwide Phase III Study Pediatric CIRB
AAML1421 COG A Phase 1/2 Study of CPX-351 (NSC# 775341; IND #129443) Alone Followed by Fludarabine; Cytarabine; and G-CSF (FLAG) for Children with Relapsed Acute Myeloid Leukemia (AML) Pediatric CIRB
AAML1531 COG Risk-stratified Therapy for Acute Myeloid Leukemia in Down Syndrome: A COG Groupwide Phase III Study Pediatric CIRB